PSMA and Integrin α <sub>v</sub> β <sub>3</sub> Dual-Targeted Radioligands for Prostate Cancer Targeted Radionuclide Therapy
Lu-PSMA-3-RGD resulted in significantly greater tumor growth delay compared to single-targeted radioligands, without inducing observable systemic toxicity. Ultimately, this dual-targeted mechanism proves highly effective, identifying the radioligand as a promising theranostic candidate for prostate cancer that merits further preclinical and clinical investigation.
Authors
- Guanglin Wang (ORCID: https://orcid.org/0000-0002-6463-119X)
- Guangming Zhou (ORCID: https://orcid.org/0000-0001-5695-2308)
- Ran Zhu (ORCID: https://orcid.org/0000-0001-9351-4702)
- Xunhao Qi
- Songlin Zhang
- Yu Qin
- Ling Yang
- Wanjia Qian
- Junhong Wang
- Xiang Zheng
- Zhihao Li
- Qian Chen
- Qian Huang
- Jie Wang
- Dong Wang
Institutions
- The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-07-26
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c01818
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00